On January 4, 2024, C4 Therapeutics, Inc. closed the transaction. The company issued 5,567,928 shares at an issue price of $4.49 per share for the gross proceeds of $24,999,996.72.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.775 USD | -3.27% | -6.01% | +2.48% |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
40.51 CNY | -0.71% | -8.35% | 2.35B | ||
5.775 USD | -3.27% | -6.01% | 411M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.48% | 411M | |
+32.12% | 50.85B | |
+0.81% | 42.82B | |
+48.88% | 42.03B | |
-4.22% | 29.55B | |
+10.85% | 26.11B | |
-22.06% | 19.13B | |
+7.49% | 13.05B | |
+26.16% | 12.16B | |
+23.23% | 12.08B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.